{"id":"solifenacin","rwe":[{"pmid":"41902910","year":"2026","title":"Efficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis.","finding":"","journal":"Pediatric nephrology (Berlin, Germany)","studyType":"Clinical Study"},{"pmid":"41854167","year":"2026","title":"Is urinary myelin basic protein the key to understanding the role of vitamin D supplementation in paediatric overactive bladder-dry? Results from a three-stage clinical investigation.","finding":"","journal":"BJU international","studyType":"Clinical Study"},{"pmid":"41852351","year":"2026","title":"Rational Design of a Carbonyl Reductase Yields a Robust Biocatalyst for Industrial Synthesis of (R)-3-Quinuclidinol.","finding":"","journal":"Biotechnology journal","studyType":"Clinical Study"},{"pmid":"41841338","year":"2026","title":"Efficacy of Solifenacin Combined with Biofeedback in Children with Neurogenic Detrusor Overactivity Caused by Primary Tethered Cord Syndrome.","finding":"","journal":"Journal of child neurology","studyType":"Clinical Study"},{"pmid":"41826414","year":"2026","title":"Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"_fda":{"id":"85807e7f-3f25-4df8-812e-fa6b281d559b","set_id":"010c0657-c907-477f-8bd7-5d455a5f50eb","openfda":{"upc":["0368462386309"],"unii":["KKA5DLD701"],"route":["ORAL"],"rxcui":["477367","477372"],"spl_id":["85807e7f-3f25-4df8-812e-fa6b281d559b"],"brand_name":["solifenacin succinate"],"spl_set_id":["010c0657-c907-477f-8bd7-5d455a5f50eb"],"package_ndc":["68462-386-30","68462-386-90","68462-386-14","68462-387-30","68462-387-90","68462-387-14"],"product_ndc":["68462-386","68462-387"],"generic_name":["SOLIFENACIN SUCCINATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SOLIFENACIN SUCCINATE"],"manufacturer_name":["Glenmark Pharmaceuticals Inc., USA"],"application_number":["ANDA209239"],"is_original_packager":[true]},"version":"6","pregnancy":["8.1 Pregnancy Risk Summary There are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. No adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at a dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (MRHD) of 10 mg/day. However, administration of doses 3.6 times and greater than the MRHD during organogenesis produced maternal toxicity in the pregnant mice and resulted in developmental toxicity and reduced fetal body weights in offspring [see Data] . In the U.S. general population, the estimated background risk of major birth defects or miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Oral administration of 14 C-solifenacin succinate to pregnant mice resulted in the recovery of radiolabel in the fetus indicating that solifenacin-related product can cross the placental barrier. In pregnant mice, administration of solifenacin succinate at a dose of 250 mg/kg/day (7.9 times the systemic exposure at the MRHD of 10 mg), resulted in an increased incidence of cleft palate and increased maternal lethality. Administration of solifenacin succinate to pregnant mice during organogenesis at greater than or equal to 3.6 times (100 mg/kg/day and greater) the systemic exposure at the MRHD, resulted in reduced fetal body weights and reduced maternal body weight gain. No embryo-fetal toxicity or teratogenicity was observed in fetuses from pregnant mice treated with solifenacin succinate at a dose of 30 mg/kg/day (1.2 times the systemic exposure at the MRHD). Administration of solifenacin succinate to pregnant rats and rabbits at a dose of 50 mg/kg/day (< 1 times and 1.8 times the systemic exposure at the MRHD, respectively), resulted in no findings of embryo-fetal toxicity. Oral pre- and post-natal administration of solifenacin succinate at 100 mg/kg/day (3.6 times the systemic exposure at the MRHD) during the period of organogenesis through weaning, resulted in reduced peripartum and postnatal survival, reduced body weight gain by the pups, and delayed physical development (eye opening and vaginal patency). An increase in the percentage of male offspring was also observed in litters from offspring (F2 generation) exposed to maternal doses of 250 mg/kg/day. There were no effects on natural delivery in mice treated with 1.2 times (30 mg/kg/day) the expected systemic exposure at the MRHD."],"overdosage":["10 OVERDOSAGE Overdosage with solifenacin succinate can potentially result in severe antimuscarinic effects and should be treated accordingly. The highest dose ingested in an accidental overdose of solifenacin succinate was 280 mg (28 times the maximum dosage) in a 5-hour period. This case was associated with mental status changes. Some cases reported a decrease in the level of consciousness. Intolerable antimuscarinic adverse reactions (fixed and dilated pupils, blurred vision, failure of heel-to-toe exam, tremors, and dry skin) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose) and resolved within 7 days following discontinuation of drug. In the event of overdose with solifenacin succinate, treat with gastric lavage and appropriate supportive measures. ECG monitoring is also recommended."],"description":["11 DESCRIPTION Solifenacin succinate tablets are a muscarinic receptor antagonist. Chemically, solifenacin succinate is a butanedioic acid compound with 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 3(R)-quinuclidinyl ester Monosuccinate having an empirical formula of C 23 H 26 N 2 O 2 •C 4 H 6 O 4 , and a molecular weight of 480.55 g/mol. The structural formula of solifenacin succinate is: Solifenacin succinate is a white to pale-yellowish-white crystal or crystalline powder. It is freely soluble or soluble in water, glacial acetic acid, dimethyl sulfoxide; soluble in methanol, very slightly soluble in acetone and ethanol. Each solifenacin succinate tablet contains 5 or 10 mg of solifenacin succinate and is formulated for oral administration. In addition to the active ingredient solifenacin succinate, the tablets also contain the following inactive ingredients: corn starch, hypromellose, lactose monohydrate, magnesium stearate, talc, titanium dioxide and triacetin. The 5 mg tablets contain the colorants iron oxide yellow and FD&C yellow# 6. The 10 mg tablets contain the colorants iron oxide yellow and FD&C Red# 40. chemical-structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Solifenacin Succinate Tablets are supplied as round, biconvex, film-coated tablets, available in bottles and unit-dose blister packages as follows: Each 5 mg tablet is yellow colored and debossed with ‘G’ on one side and ‘51’ on the other side and is available as follows: Bottle of 30 with child-resistant closure, NDC 68462-386-30 Bottle of 90 with child-resistant closure, NDC 68462-386-90 Unit-Dose Pack of 100 NDC 68462-386-14 Each 10 mg tablet is pink colored and debossed with ‘G’ on one side and ‘52’ on the other side and is available as follows: Bottle of 30 with child-resistant closure, NDC 68462-387-30 Bottle of 90 with child-resistant closure, NDC 68462-387-90 Unit-Dose Pack of 100 NDC 68462-387-14 Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]."],"effective_time":"20260128","clinical_studies":["14 CLINICAL STUDIES Solifenacin succinate was evaluated in four twelve-week, double-blind, randomized, placebo-controlled, parallel group, multicenter clinical trials for the treatment of overactive bladder in adult patients having symptoms of urinary frequency, urgency, and/or urge or mixed incontinence (with a predominance of urge). Entry criteria required that patients have symptoms of overactive bladder for ≥3 months duration. These studies involved 3027 patients (1811 on solifenacin succinate and 1216 on placebo), and approximately 90% of these patients completed the 12-week studies. Two of the four studies evaluated the 5 and 10 mg solifenacin succinate doses (Studies 1 and 2) and the other two evaluated only the 10 mg dose (Studies 3 and 4). All patients completing the 12-week studies were eligible to enter an open-label, long-term extension study (Study 5) and 81% of patients enrolling completed the additional 40-week treatment period. The majority of patients were Caucasian (93%) and female (80%) with a mean age of 58 years. The primary endpoint in all four trials was the mean change from baseline to 12 weeks in number of micturitions/24 hours. Secondary endpoints included mean change from baseline to 12 weeks in number of incontinence episodes/24 hours, and mean volume voided per micturition. The efficacy of solifenacin succinate was similar across patient age groups and gender. The mean reduction in the number of micturitions per 24 hours was significantly greater with solifenacin succinate 5 mg (2.3; p<0.001) and solifenacin succinate 10 mg (2.7; p<0.001) compared to placebo (1.4). The mean reduction in the number of incontinence episodes per 24 hours was significantly greater with solifenacin succinate 5 mg (1.5; p<0.001) and solifenacin succinate 10 mg (1.8; p<0.001) treatment groups compared to the placebo treatment group (1.1). The mean increase in the volume voided per micturition was significantly greater with solifenacin succinate 5 mg (32.3 mL; p<0.001) and solifenacin succinate 10 mg (42.5 mL; p<0.001) compared with placebo (8.5 mL). The results for the primary and secondary endpoints in the four individual 12-week clinical studies of solifenacin succinate are reported in Tables 3 through 6. Table 3: Mean Changes from Baseline to Week 12 in Efficacy Endpoints in Study 1 Parameter Placebo (N=253) Mean (SE) Solifenacin Succinate 5 mg (N=266) Mean (SE) Solifenacin Succinate 10 mg (N=264) Mean (SE) Urinary Frequency (Number of Micturitions/24 hours) 1 Baseline Reduction P value vs. placebo 12.2 (0.26) 1.2 (0.21) 12.1 (0.24) 2.2 (0.18) < 0.001 12.3 (0.24) 2.6 (0.20) < 0.001 Number of Incontinence Episodes/24 hours 2 Baseline Reduction P value vs. placebo 2.7 (0.23) 0.8 (0.18) 2.6 (0.22) 1.4 (0.15) < 0.01 2.6 (0.23) 1.5 (0.18) < 0.01 Volume Voided per Micturition [mL] 2 Baseline Increase P value vs. placebo 143.8 (3.37) 7.4 (2.28) 149.6 (3.35) 32.9 (2.92) < 0.001 147.2 (3.15) 39.2 (3.11) < 0.001 1 Primary endpoint 2 Secondary endpoint Table 4: Mean Changes from Baseline to Week 12 in Efficacy Endpoints in Study 2 Parameter Placebo (N=281) Mean (SE) Solifenacin Succinate 5 mg (N=286) Mean (SE) Solifenacin Succinate 10 mg (N=290) Mean (SE) Urinary Frequency (Number of Micturitions/24 hours) 1 Baseline Reduction P value vs. placebo 12.3 (0.23) 1.7 (0.19) 12.1 (0.23) 2.4 (0.17) < 0.001 12.1 (0.21) 2.9 (0.18) < 0.001 Number of Incontinence Episodes/24 hours 2 Baseline Reduction P value vs. placebo 3.2 (0.24) 1.3 (0.19) 2.6 (0.18) 1.6 (0.16) < 0.01 2.8 (0.20) 1.6 (0.18) 0.016 Volume Voided per Micturition [mL] 2 Baseline Increase P value vs. placebo 147.2 (3.18) 11.3 (2.52) 148.5 (3.16) 31.8 (2.94) < 0.001 145.9 (3.42) 36.6 (3.04) < 0.001 1 Primary endpoint 2 Secondary endpoint Table 5: Mean Changes from Baseline to Week 12 in Efficacy Endpoints in Study 3 Parameter Placebo (N=309) Mean (SE) Solifenacin Succinate 10 mg (N=306) Mean (SE) Urinary Frequency (Number of Micturitions/24 hours) 1 Baseline Reduction P value vs. placebo 11.5 (0.18) 1.5 (0.15) 11.7 (0.18) 3 (0.15) < 0.001 Number of Incontinence Episodes/24 hours 2 Baseline Reduction P value vs. placebo 3 (0.20) 1.1 (0.16) 3.1 (0.22) 2 (0.19) < 0.001 Volume Voided per Micturition [mL] 2 Baseline Increase P value vs. placebo 190.3 (5.48) 2.7 (3.15) 183.5 (4.97) 47.2 (3.79) < 0.001 1 Primary endpoint 2 Secondary endpoint Table 6: Mean Changes from Baseline to Week 12 in Efficacy Endpoints in Study 4 Parameter Placebo (N=295) Mean (SE) Solifenacin Succinate 10 mg (N=298) Mean (SE) Urinary Frequency (Number of Micturitions/24 hours) 1 Baseline Reduction P value vs. placebo 11.8 (0.18) 1.3 (0.16) 11.5 (0.18) 2.4 (0.15) < 0.001 Number of Incontinence Episodes/24 hours 2 Baseline Reduction P value vs. placebo 2.9 (0.18) 1.2 (0.15) 2.9 (0.17) 2 (0.15) < 0.001 Volume Voided per Micturition [mL] 2 Baseline Increase P value vs. placebo 175.7 (4.44) 13 (3.45) 174.1 (4.15) 46.4 (3.73) < 0.001 1 Primary endpoint 2 Secondary endpoint"],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology The effect of 10 mg and 30 mg solifenacin succinate (three times the maximum recommended dose) on the QT interval was evaluated at the time of peak plasma concentration of solifenacin in a multi-dose, randomized, double-blind, placebo and positive-controlled (moxifloxacin 400 mg) trial [ see Warnings and Precautions ( 5.6 ) ]. After receiving placebo and moxifloxacin sequentially, subjects were randomized to one of two treatment groups. One group (n=51) completed 3 additional sequential periods of dosing with solifenacin succinate 10, 20, and 30 mg while the second group (n=25) in parallel completed a sequence of placebo and moxifloxacin. Study subjects were female volunteers aged 19 to 79 years. The 30 mg dose of solifenacin succinate (three times the highest recommended dose) was chosen for use in this study because this dose results in a solifenacin exposure that covers those observed upon coadministration of 10 mg solifenacin succinate with strong CYP3A4 inhibitors (e.g., ketoconazole, 400 mg). Due to the sequential dose escalating nature of the study, baseline ECG measurements were separated from the final QT assessment (of the 30 mg dose level) by 33 days. The median difference from baseline in heart rate associated with the 10 and 30 mg doses of solifenacin succinate compared to placebo was -2 and 0 beats/minute, respectively. Because a significant period effect on QTc was observed, the QTc effects were analyzed utilizing the parallel placebo control arm rather than the pre-specified intra-patient analysis. Representative results are shown in Table 2. Table 2: QTc changes in msec (90% CI) from baseline at T max (relative to placebo) 1 Drug/Dose Fridericia method (using mean difference) Solifenacin succinate 10 mg 2 (-3,6) Solifenacin succinate 30 mg 8 (4,13) 1. Results displayed are those derived from the parallel design portion of the study and represent the comparison of Group 1 to time-matched placebo effects in Group 2 Moxifloxacin was included as a positive control in this study and, given the length of the study, its effect on the QT interval was evaluated in 3 different sessions. The placebo-subtracted mean changes (90% CI) in QTcF for moxifloxacin in the three sessions were 11 (7, 14), 12 (8, 17), and 16 (12, 21), respectively. The QT interval prolonging effect of the highest solifenacin succinate dose (three times the maximum therapeutic dose) studied was not as large as that of the positive control moxifloxacin at its recommended dose. However, the confidence intervals overlapped, and this study was not designed to draw direct statistical conclusions between the drugs or the dose levels."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively. The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered. Effect of Food Solifenacin succinate may be administered without regard to meals. A single 10 mg dose administration of solifenacin succinate with food increased C max and AUC of solifenacin by 4% and 3%, respectively. Distribution Solifenacin is approximately 98% ( in vivo ) bound to human plasma proteins, principally to ∝ 1 -acid glycoprotein. Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L. Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours. Metabolism Solifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist. The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of the tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing. Excretion Following the administration of 10 mg of 14 C-solifenacin succinate to healthy volunteers, 69% of the radioactivity was recovered in the urine and 23% in the feces over 26 days. Less than 15% (as mean value) of the dose was recovered in the urine as intact solifenacin. The major metabolites identified in urine were N-oxide of solifenacin, 4R-hydroxy solifenacin, and 4R-hydroxy-N-oxide of solifenacin and, in feces, 4R-hydroxy solifenacin. Specific Populations Geriatric Patients Multiple dose studies of solifenacin succinate in geriatric volunteers (65 to 80 years) showed that C max , AUC and t 1/2 values of solifenacin were 20 to 25% higher compared to the younger adult volunteers (18 to 55 years) [8.5]. Patients with Renal Impairment In studies with solifenacin succinate 10 mg, there was a 2.1-fold increase in AUC and a 1.6-fold increase in t 1/2 of solifenacin in patients with severe renal impairment compared to subjects with normal renal function [8.6]. Patients with Hepatic Impairment In studies with solifenacin succinate 10 mg, there was a 2-fold increase in the t 1/2 and a 35% increase in AUC of solifenacin in patients with moderate hepatic impairment compared to subjects with normal hepatic function [8.7]. Solifenacin succinate has not been studied in patients with severe hepatic impairment. Drug Interaction Studies Strong CYP3A4 Inhibitors In a crossover study, following blockade of CYP3A4 by coadministration of the strong CYP3A4 inhibitor, ketoconazole 400 mg once daily for 21 days, the mean C max and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively [ see Dosage and Administration (2.4) and Drug Interactions (7.1) ]. CYP3A4 Inducers Because solifenacin is a substrate of CYP3A4, inducers of CYP3A4 may decrease the concentration of solifenacin. Warfarin In a crossover study, subjects received a single oral dose of warfarin 25 mg on the 10 th day of dosing with either solifenacin succinate 10 mg or matching placebo once daily for 16 days. For R -warfarin, when it was coadministered with solifenacin succinate, the mean C max increased by 3% and AUC decreased by 2%. For S -warfarin, when it was coadministered with solifenacin succinate, the mean C max and AUC increased by 5% and 1%, respectively. Oral Contraceptives In a crossover study, subjects received 2 cycles of 21 days of oral contraceptives containing 30 ug ethinyl estradiol and 150 ug levonorgestrel. During the second cycle, subjects received additional solifenacin succinate 10 mg or matching placebo once daily for 10 days starting from the 12 th day of receipt of oral contraceptives. For ethinyl estradiol, when it was administered with solifenacin succinate, the mean C max and AUC increased by 2% and 3%, respectively. For levonorgestrel, when it was administered with solifenacin succinate, the mean C max and AUC decreased by 1%. Digoxin In a crossover study, subjects received digoxin (loading dose of 0.25 mg on day 1, followed by 0.125 mg from days 2 to 8) for 8 days. Consecutively, they received solifenacin succinate 10 mg or matching placebo with digoxin 0.125 mg for an additional 10 days. When digoxin was coadministered with solifenacin succinate, the mean C max and AUC increased by 13% and 4%, respectively. Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies demonstrated that, at therapeutic concentrations, solifenacin does not inhibit CYP1A1/2, 2C9, 2C19, 2D6, or 3A4 derived from human liver microsomes."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions (> 4% in solifenacin succinate-treated patients and > placebo-treated patients) were dry mouth and constipation at both 5 mg and 10 mg doses; and urinary tract infection and blurred vision at the 10 mg dose ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Solifenacin succinate has been evaluated for safety in 1811 adult patients in four randomized, placebo-controlled trials (Studies 1 to 4) [see Clinical Studies ( 14 )] . Expected adverse reactions of antimuscarinic agents are dry mouth, constipation, blurred vision (accommodation abnormalities), urinary retention, and dry eyes. The incidence of dry mouth and constipation in patients treated with solifenacin succinate was higher in the 10 mg dose group compared to the 5 mg dose group. In the four 12-week double-blind clinical trials, severe fecal impaction, colonic obstruction, and intestinal obstruction were reported in one patient each, all in the solifenacin succinate 10 mg group. Angioneurotic edema was reported in one patient taking solifenacin succinate 5 mg. Compared to 12 weeks of treatment with solifenacin succinate, the incidence and severity of adverse reactions were similar in patients who remained on drug for up to 12 months in Study 5 [ see Clinical Studies ( 14 ) ]. The most frequent adverse reaction leading to study discontinuation was dry mouth (1.5%). Table 1 lists the rates of identified adverse reactions, in the four randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with solifenacin succinate 5 or 10 mg once daily for up to 12 weeks. Table 1: Adverse Reactions Reported by ≥ 1% of Patients and Exceeding Placebo in Studies 1, 2, 3 and 4 Placebo (%) Solifenacin Succinate 5 mg (%) Solifenacin Succinate 10 mg (%) Number of Patients 1216 578 1233 GASTROINTESTINAL DISORDERS Dry Mouth 4.2 10.9 27.6 Constipation 2.9 5.4 13.4 Nausea 2 1.7 3.3 Dyspepsia 1 1.4 3.9 Abdominal Pain Upper 1 1.9 1.2 Vomiting NOS 0.9 0.2 1.1 INFECTIONS AND INFESTATIONS Urinary Tract Infection NOS 2.8 2.8 4.8 Influenza 1.3 2.2 0.9 Pharyngitis NOS 1 0.3 1.1 NERVOUS SYSTEM DISORDERS Dizziness 1.8 1.9 1.8 EYE DISORDERS Vision Blurred 1.8 3.8 4.8 Dry Eyes NOS 0.6 0.3 1.6 RENAL AND URINARY DISORDERS Urinary Retention 0.6 0 1.4 GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Edema Lower Limb 0.7 0.3 1.1 Fatigue 1.1 1 2.1 PSYCHIATRIC DISORDERS Depression NOS 0.8 1.2 0.8 RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Cough 0.2 0.2 1.1 VASCULAR DISORDERS Hypertension NOS 0.6 1.4 0.5 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of solifenacin succinate in the U.S. and/or outside of the U.S. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. General disorders and administration site conditions : peripheral edema, hypersensitivity reactions (including angioedema with airway obstruction, rash, pruritus, urticaria, anaphylactic reaction); Nervous system disorders : dizziness, headache, confusion, hallucinations, delirium, somnolence; Cardiac disorders : QT prolongation, Torsade de Pointes, atrial fibrillation, tachycardia, palpitations; Hepatobiliary disorders : liver disorders mostly characterized by abnormal liver function tests, AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gamma-glutamyl transferase); Renal and urinary disorders : renal impairment, urinary retention; Metabolism and nutrition disorders : decreased appetite, hyperkalemia; Skin and subcutaneous tissue disorders : exfoliative dermatitis, erythema multiforme, dry skin; Eye disorders : glaucoma; Gastrointestinal disorders : gastroesophageal reflux disease, ileus, vomiting, abdominal pain, dysgeusia, sialadenitis; Respiratory, thoracic and mediastinal disorders : dysphonia, nasal dryness; Musculoskeletal and connective tissue disorders : muscular weakness."],"contraindications":["4 CONTRAINDICATIONS Solifenacin succinate tablets are contraindicated in patients: • With urinary retention [ see Warnings and Precautions ( 5.2 ) ], • With gastric retention [ see Warnings and Precautions ( 5.3 ) ], • With uncontrolled narrow-angle glaucoma [ see Warnings and Precautions ( 5.5 ) ], and • Who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. Reported adverse reactions have included anaphylaxis and angioedema [ see Adverse Reactions ( 6.2 ) ]. • Urinary retention ( 4 , 5.2 ). • Gastric retention ( 4 , 5.3 ). • Uncontrolled narrow-angle glaucoma ( 4 , 5.5 ). • Hypersensitivity to this product or any of its components ( 4 , 5.1 , 6.2 )."],"drug_interactions":["7 DRUG INTERACTIONS CYP3A4 Inhibitors : Do not exceed the 5 mg dose of solifenacin succinate with concomitant use of strong CYP3A4 inhibitors ( 7.1 ). 7.1 Strong CYP3A4 Inhibitors Solifenacin is a substrate of CYP3A4. Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [ see Clinical Pharmacology ( 12.3 ) ]. The dosage of solifenacin succinate greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [ see Dosage and Administration ( 2.4 ) ]."],"mechanism_of_action":["12.1 Mechanism of Action Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of 10 mg and 30 mg solifenacin succinate (three times the maximum recommended dose) on the QT interval was evaluated at the time of peak plasma concentration of solifenacin in a multi-dose, randomized, double-blind, placebo and positive-controlled (moxifloxacin 400 mg) trial [ see Warnings and Precautions ( 5.6 ) ]. After receiving placebo and moxifloxacin sequentially, subjects were randomized to one of two treatment groups. One group (n=51) completed 3 additional sequential periods of dosing with solifenacin succinate 10, 20, and 30 mg while the second group (n=25) in parallel completed a sequence of placebo and moxifloxacin. Study subjects were female volunteers aged 19 to 79 years. The 30 mg dose of solifenacin succinate (three times the highest recommended dose) was chosen for use in this study because this dose results in a solifenacin exposure that covers those observed upon coadministration of 10 mg solifenacin succinate with strong CYP3A4 inhibitors (e.g., ketoconazole, 400 mg). Due to the sequential dose escalating nature of the study, baseline ECG measurements were separated from the final QT assessment (of the 30 mg dose level) by 33 days. The median difference from baseline in heart rate associated with the 10 and 30 mg doses of solifenacin succinate compared to placebo was -2 and 0 beats/minute, respectively. Because a significant period effect on QTc was observed, the QTc effects were analyzed utilizing the parallel placebo control arm rather than the pre-specified intra-patient analysis. Representative results are shown in Table 2. Table 2: QTc changes in msec (90% CI) from baseline at T max (relative to placebo) 1 Drug/Dose Fridericia method (using mean difference) Solifenacin succinate 10 mg 2 (-3,6) Solifenacin succinate 30 mg 8 (4,13) 1. Results displayed are those derived from the parallel design portion of the study and represent the comparison of Group 1 to time-matched placebo effects in Group 2 Moxifloxacin was included as a positive control in this study and, given the length of the study, its effect on the QT interval was evaluated in 3 different sessions. The placebo-subtracted mean changes (90% CI) in QTcF for moxifloxacin in the three sessions were 11 (7, 14), 12 (8, 17), and 16 (12, 21), respectively. The QT interval prolonging effect of the highest solifenacin succinate dose (three times the maximum therapeutic dose) studied was not as large as that of the positive control moxifloxacin at its recommended dose. However, the confidence intervals overlapped, and this study was not designed to draw direct statistical conclusions between the drugs or the dose levels. 12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate in healthy volunteers, peak plasma concentrations (C max ) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablets, respectively. The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered. Effect of Food Solifenacin succinate may be administered without regard to meals. A single 10 mg dose administration of solifenacin succinate with food increased C max and AUC of solifenacin by 4% and 3%, respectively. Distribution Solifenacin is approximately 98% ( in vivo ) bound to human plasma proteins, principally to ∝ 1 -acid glycoprotein. Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600 L. Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45 to 68 hours. Metabolism Solifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist. The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of the tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing. Excretion Following the administration of 10 mg of 14 C-solifenacin succinate to healthy volunteers, 69% of the radioactivity was recovered in the urine and 23% in the feces over 26 days. Less than 15% (as mean value) of the dose was recovered in the urine as intact solifenacin. The major metabolites identified in urine were N-oxide of solifenacin, 4R-hydroxy solifenacin, and 4R-hydroxy-N-oxide of solifenacin and, in feces, 4R-hydroxy solifenacin. Specific Populations Geriatric Patients Multiple dose studies of solifenacin succinate in geriatric volunteers (65 to 80 years) showed that C max , AUC and t 1/2 values of solifenacin were 20 to 25% higher compared to the younger adult volunteers (18 to 55 years) [8.5]. Patients with Renal Impairment In studies with solifenacin succinate 10 mg, there was a 2.1-fold increase in AUC and a 1.6-fold increase in t 1/2 of solifenacin in patients with severe renal impairment compared to subjects with normal renal function [8.6]. Patients with Hepatic Impairment In studies with solifenacin succinate 10 mg, there was a 2-fold increase in the t 1/2 and a 35% increase in AUC of solifenacin in patients with moderate hepatic impairment compared to subjects with normal hepatic function [8.7]. Solifenacin succinate has not been studied in patients with severe hepatic impairment. Drug Interaction Studies Strong CYP3A4 Inhibitors In a crossover study, following blockade of CYP3A4 by coadministration of the strong CYP3A4 inhibitor, ketoconazole 400 mg once daily for 21 days, the mean C max and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively [ see Dosage and Administration (2.4) and Drug Interactions (7.1) ]. CYP3A4 Inducers Because solifenacin is a substrate of CYP3A4, inducers of CYP3A4 may decrease the concentration of solifenacin. Warfarin In a crossover study, subjects received a single oral dose of warfarin 25 mg on the 10 th day of dosing with either solifenacin succinate 10 mg or matching placebo once daily for 16 days. For R -warfarin, when it was coadministered with solifenacin succinate, the mean C max increased by 3% and AUC decreased by 2%. For S -warfarin, when it was coadministered with solifenacin succinate, the mean C max and AUC increased by 5% and 1%, respectively. Oral Contraceptives In a crossover study, subjects received 2 cycles of 21 days of oral contraceptives containing 30 ug ethinyl estradiol and 150 ug levonorgestrel. During the second cycle, subjects received additional solifenacin succinate 10 mg or matching placebo once daily for 10 days starting from the 12 th day of receipt of oral contraceptives. For ethinyl estradiol, when it was administered with solifenacin succinate, the mean C max and AUC increased by 2% and 3%, respectively. For levonorgestrel, when it was administered with solifenacin succinate, the mean C max and AUC decreased by 1%. Digoxin In a crossover study, subjects received digoxin (loading dose of 0.25 mg on day 1, followed by 0.125 mg from days 2 to 8) for 8 days. Consecutively, they received solifenacin succinate 10 mg or matching placebo with digoxin 0.125 mg for an additional 10 days. When digoxin was coadministered with solifenacin succinate, the mean C max and AUC increased by 13% and 4%, respectively. Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies demonstrated that, at therapeutic concentrations, solifenacin does not inhibit CYP1A1/2, 2C9, 2C19, 2D6, or 3A4 derived from human liver microsomes."],"indications_and_usage":["1 INDICATIONS AND USAGE Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Angioedema and Anaphylactic Reactions : Promptly discontinue solifenacin succinate and provide appropriate therapy ( 5.1 ) • Urinary Retention : Solifenacin succinate is not recommended for use in patients with clinically significant bladder outlet obstruction ( 5.2 ). • Gastrointestinal Disorders : Solifenacin succinate is not recommended for use in patients with decreased gastrointestinal motility ( 5.3 ). • Central Nervous System Effects : Somnolence has been reported with solifenacin succinate . Advise patients not to drive or operate heavy machinery until they know how solifenacin succinate affects them ( 5.4 ). • Controlled Narrow-Angle Glaucoma : Use solifenacin succinate with caution in patients being treated for narrow-angle glaucoma ( 5.5 ). • QT Prolongation in Patients at High Risk of QT Prolongation : Solifenacin succinate is not recommended for use in patients at high risk of QT prolongation, including patients with a known history of QT prolongation and patients taking medications known to prolong the QT interval ( 5.6 ). 5.1 Angioedema and Anaphylactic Reactions Angioedema of the face, lips, tongue, and/or larynx have been reported with solifenacin succinate. In some cases, angioedema occurred after the first dose, however, cases have been reported to occur hours after the first dose or after multiple doses. Anaphylactic reactions have also been reported in patients treated with solifenacin succinate. Angioedema associated with upper airway swelling and anaphylactic reactions may be life-threatening. Solifenacin succinate is contraindicated in patients with a known or suspected hypersensitivity to solifenacin succinate [ see Contraindications ( 4 ) ]. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue solifenacin succinate and provide appropriate therapy and/or measures necessary to ensure a patent airway. 5.2 Urinary Retention The use of solifenacin succinate, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. The use of solifenacin succinate is not recommended in patients with clinically significant bladder outlet obstruction and is contraindicated in patients with urinary retention [ see Contraindications ( 4 ) ]. 5.3 Gastrointestinal Disorders The use of solifenacin succinate, like other antimuscarinic drugs, in patients with conditions associated with decreased gastrointestinal motility may result in further decreased gastrointestinal motility. Solifenacin succinate is contraindicated in patients with gastric retention [ see Contraindications ( 4 ) ]. The use of solifenacin succinate is not recommended in patients with conditions associated with decreased gastrointestinal motility. 5.4 Central Nervous System Effects Solifenacin succinate is associated with antimuscarinic central nervous system (CNS) adverse reactions [ see Adverse Reactions ( 6.2 ) ]. A variety of CNS antimuscarinic adverse reactions have been reported, including headache, confusion, hallucinations, and somnolence. Monitor patients for signs of antimuscarinic CNS adverse reactions, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how solifenacin succinate affects them. If a patient experiences antimuscarinic CNS adverse reactions, consider dose reduction or drug discontinuation. 5.5 Controlled Narrow-Angle Glaucoma Solifenacin succinate should be used with caution in patients being treated for narrow-angle glaucoma [ see Contraindications ( 4 ) ]. 5.6 QT Prolongation in Patients at High Risk of QT Prolongation In a study of the effect of solifenacin succinate on the QT interval conducted in 76 healthy women [ see Clinical Pharmacology ( 12.2 ) ], solifenacin succinate 30 mg (three times the largest maximum recommended dose in adult patients) was associated with a mean increase in the Fridericia-corrected QT interval of 8 msec (90% CI, 4, 13). The QT prolonging effect appeared less with solifenacin succinate 10 mg than with solifenacin succinate 30 mg, and the effect of solifenacin succinate 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. The use of solifenacin succinate is not recommended in patients at high risk of QT prolongation, including patients with a known history of QT prolongation and patients who are taking medications known to prolong the QT interval."],"clinical_studies_table":["Baseline ReductionP value vs. placeboBaseline ReductionP value vs. placeboBaseline IncreaseP value vs. placebo
ParameterPlacebo(N=253)Mean (SE)Solifenacin Succinate 5 mg (N=266)Mean (SE)Solifenacin Succinate 10 mg (N=264)Mean (SE)
Urinary Frequency (Number of Micturitions/24 hours)1
12.2 (0.26)1.2 (0.21)12.1 (0.24)2.2 (0.18)< 0.00112.3 (0.24)2.6 (0.20)< 0.001
Number of Incontinence Episodes/24 hours2
2.7 (0.23)0.8 (0.18)2.6 (0.22)1.4 (0.15)< 0.012.6 (0.23)1.5 (0.18)< 0.01
Volume Voided per Micturition [mL]2
143.8 (3.37)7.4 (2.28)149.6 (3.35)32.9 (2.92)< 0.001147.2 (3.15)39.2 (3.11)< 0.001
","Urinary Frequency (Number of Micturitions/24 hours)1Baseline ReductionP value vs. placebo12.3 (0.23)1.7 (0.19)12.1 (0.23)2.4 (0.17)< 0.00112.1 (0.21)2.9 (0.18)< 0.001Number of Incontinence Episodes/24 hours2Baseline ReductionP value vs. placebo3.2 (0.24)1.3 (0.19)2.6 (0.18)1.6 (0.16)< 0.012.8 (0.20)1.6 (0.18)0.016Volume Voided per Micturition [mL]2Baseline IncreaseP value vs. placebo147.2 (3.18)11.3 (2.52)148.5 (3.16)31.8 (2.94)< 0.001145.9 (3.42)36.6 (3.04)< 0.001
ParameterPlacebo (N=281) Mean (SE)Solifenacin Succinate 5 mg (N=286) Mean (SE)Solifenacin Succinate 10 mg (N=290) Mean (SE)
","Baseline ReductionP value vs. placeboBaseline ReductionP value vs. placeboBaseline IncreaseP value vs. placebo
ParameterPlacebo (N=309) Mean (SE)Solifenacin Succinate 10 mg (N=306) Mean (SE)
Urinary Frequency (Number of Micturitions/24 hours)1
11.5 (0.18)1.5 (0.15)11.7 (0.18)3 (0.15)< 0.001
Number of Incontinence Episodes/24 hours2
3 (0.20)1.1 (0.16)3.1 (0.22)2 (0.19)< 0.001
Volume Voided per Micturition [mL]2
190.3 (5.48)2.7 (3.15)183.5 (4.97)47.2 (3.79)< 0.001
","Baseline ReductionP value vs. placeboBaseline ReductionP value vs. placeboBaseline IncreaseP value vs. placebo
ParameterPlacebo(N=295)Mean (SE)Solifenacin Succinate 10 mg (N=298)Mean (SE)
Urinary Frequency (Number of Micturitions/24 hours)1
11.8 (0.18)1.3 (0.16)11.5 (0.18)2.4 (0.15)< 0.001
Number of Incontinence Episodes/24 hours2
2.9 (0.18)1.2 (0.15)2.9 (0.17)2 (0.15)< 0.001
Volume Voided per Micturition [mL]2
175.7 (4.44)13 (3.45)174.1 (4.15)46.4 (3.73)< 0.001
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No increase in tumors was found following the administration of solifenacin succinate to male and female mice for 104 weeks at doses up to 200 mg/kg/day (5 and 9 times, respectively, of the exposure at the maximum recommended human dose [MRHD] of 10 mg), and male and female rats for 104 weeks at doses up to 20 and 15 mg/kg/day, respectively (<1 times the exposure at the MRHD). Solifenacin succinate was not mutagenic in the in vitro Salmonella typhimurium or Escherichia coli microbial mutagenicity test or chromosomal aberration test in human peripheral blood lymphocytes with or without metabolic activation or in the in vivo micronucleus test in rats. Solifenacin succinate had no effect on reproductive function, fertility, or early embryonic development of the fetus in male and female mice treated with 250 mg/kg/day (13 times the exposure at the MRHD) of solifenacin succinate, and in male rats treated with 50 mg/kg/day (<1 times the exposure at the MRHD) and female rats treated with 100 mg/kg/day (1.7 times the exposure at the MRHD) of solifenacin succinate. 13.2 Animal Toxicology and/or Pharmacology Juvenile Animal Toxicology Data Dose-related increased mortality without preceding clinical signs occurred in juvenile mice treated before weaning for a duration of 12 weeks, from day 10 after birth, with doses that achieved a pharmacological effect. Animals dosed from postnatal day 10 onwards had higher mortality compared to the mortality in adult mice. No increased frequency in mortality was observed in juvenile mice that were treated after weaning for a duration of 4 weeks, from day 21 after birth onwards. Plasma exposure at postnatal day 10 was higher than in adult mice; the systemic exposure at postnatal day 21 was comparable to the systemic exposure in adult mice."],"pharmacodynamics_table":["
Table 2: QTc changes in msec (90% CI) from baseline at Tmax (relative to placebo)1
Drug/DoseFridericia method (using mean difference)
Solifenacin succinate 10 mg2 (-3,6)
Solifenacin succinate 30 mg8 (4,13)
"],"adverse_reactions_table":["
Table 1: Adverse Reactions Reported by ≥ 1% of Patients and Exceeding Placebo in Studies 1, 2, 3 and 4
Placebo (%)Solifenacin Succinate 5 mg (%)Solifenacin Succinate 10 mg (%)
Number of Patients12165781233
GASTROINTESTINAL DISORDERS
Dry Mouth4.210.927.6
Constipation2.95.413.4
Nausea21.73.3
Dyspepsia11.43.9
Abdominal Pain Upper11.91.2
Vomiting NOS0.90.21.1
INFECTIONS AND INFESTATIONS
Urinary Tract Infection NOS2.82.84.8
Influenza1.32.20.9
Pharyngitis NOS10.31.1
NERVOUS SYSTEM DISORDERS
Dizziness1.81.91.8
EYE DISORDERS
Vision Blurred1.83.84.8
Dry Eyes NOS0.60.31.6
RENAL AND URINARY DISORDERS
Urinary Retention0.601.4
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
Edema Lower Limb0.70.31.1
Fatigue1.112.1
PSYCHIATRIC DISORDERS
Depression NOS0.81.20.8
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
Cough0.20.21.1
VASCULAR DISORDERS
Hypertension NOS0.61.40.5
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information) . Angioedema and Anaphylactic Reactions Inform patients that angioedema and anaphylactic reactions have been reported in patients treated with solifenacin succinate tablets. Angioedema and anaphylactic reactions may be life-threatening. Advise patients to promptly discontinue solifenacin succinate tablets therapy and seek immediate attention if they experience edema of the tongue or laryngopharynx, or difficulty breathing [see Contraindications (4) and Warnings and Precautions (5.1) ] . Urinary Retention Inform patients that solifenacin succinate tablets may cause urinary retention in patients with conditions associated with bladder outlet obstruction [see Warnings and Precautions (5.2) ] . Gastrointestinal Disorders Inform patients that solifenacin succinate tablets may cause further decrease in gastrointestinal motility in patients with conditions associated with decreased gastrointestinal motility. Solifenacin succinate tablets has been associated with constipation and dry mouth. Advise patients to contact their health care providers if they experience severe abdominal pain or become constipated for 3 or more days [ see Warnings and Precautions (5.3) ]. Central Nervous System Effects Because solifenacin succinate tablets, like other antimuscarinic agents, may cause central nervous system effects or blurred vision, advise patients to exercise caution in decisions to engage in potentially dangerous activities until the drug’s effect on the patient has been determined [see Warnings and Precautions (5.4) ] . Narrow-Angle Glaucoma Inform patients that solifenacin succinate tablets, like other antimuscarinics, may cause worsening of the glaucoma condition in patients with narrow-angle glaucoma [see Warnings and Precautions (5.5) ] . Dry Skin Inform patients that solifenacin succinate tablets, like other antimuscarinics, may cause dry skin due to decreased sweating. Heat prostration due to decreased sweating can occur when solifenacin succinate tablets is used in a hot environment [see Adverse Reactions (6.2) ] . Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1(888) 721-7115 www.glenmarkpharma-us.com August 2025 glenmark-logo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • 5 mg tablet taken orally once daily, and if well tolerated may be increased to 10 mg once daily ( 2.1 ). • Do not exceed the 5 mg dose of solifenacin succinate tablets in patients with: • Severe renal impairment creatinine clearance <30 mL/min/1.73 m 2 ( 2.2 , 8.6 ). • Moderate hepatic impairment (Child-Pugh B). Solifenacin succinate tablets are not recommended in patients with severe hepatic impairment (Child- Pugh C) ( 2.3 , 8.7 ). • Concomitant use of strong CYP3A4 inhibitors ( 2.4 , 7.1 ). 2.1 Dosing Information The recommended oral dose of solifenacin succinate tablets is 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be increased to 10 mg once daily. Solifenacin succinate tablets should be taken with water and swallowed whole. Solifenacin succinate tablets can be administered with or without food. 2.2 Dosing Recommendations in Patients with Renal Impairment Do not exceed 5 mg once daily in patients with severe renal impairment (CL cr <30 mL/min/1.73 m 2 ) [ see Use in Specific Populations (8.6) ]. 2.3 Dosing Recommendations in Patients with Hepatic Impairment Do not exceed 5 mg once daily in patients with moderate hepatic impairment (Child-Pugh B). Do not use of solifenacin succinate tablets in patients with severe hepatic impairment (Child-Pugh C) [ see Use in Specific Populations (8.7) ]. 2.4 Dosing Recommendations in Patients Taking CYP3A4 Inhibitors Do not exceed 5 mg once daily when solifenacin succinate tablets are administered with strong CYP3A4 inhibitors such as ketoconazole [ see Drug Interactions ( 7.1 ) ]."],"spl_product_data_elements":["solifenacin succinate solifenacin succinate SOLIFENACIN SUCCINATE SOLIFENACIN STARCH, CORN LACTOSE MONOHYDRATE HYPROMELLOSE, UNSPECIFIED MAGNESIUM STEARATE TRIACETIN TALC TITANIUM DIOXIDE FD&C YELLOW NO. 6 FERRIC OXIDE YELLOW biconvex G;51 solifenacin succinate solifenacin succinate SOLIFENACIN SUCCINATE SOLIFENACIN STARCH, CORN LACTOSE MONOHYDRATE HYPROMELLOSE, UNSPECIFIED MAGNESIUM STEARATE TRIACETIN TALC TITANIUM DIOXIDE FERRIC OXIDE YELLOW FD&C RED NO. 40 biconvex G;52"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS The 5 mg tablets are yellow colored, round, biconvex, film-coated tablets with ‘G’ debossed on one side and ‘51’ debossed on the other side. The 10 mg tablets are pink colored, round, biconvex, film-coated tablets with ‘G’ debossed on one side and ‘52’ debossed on the other side. Tablets: 5 mg and 10 mg ( 3 )."],"spl_patient_package_insert":["Patient Information Solifenacin Succinate (SOE-li-FEN-a-sin SUX-i-nate) Tablets Read the Patient Information that comes with solifenacin succinate tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. What are solifenacin succinate tablets? Solifenacin succinate tablets are a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder : • Urge urinary incontinence: a strong need to urinate with leaking or wetting accidents • Urgency: a strong need to urinate right away • Frequency: urinating often Solifenacin succinate tablets 5 mg and 10 mg are not approved for use in children. Who should not take solifenacin succinate tablets? Do not take solifenacin succinate tablets if you: • are not able to empty your bladder (urinary retention) • have delayed or slow emptying of your stomach (gastric retention) • have an eye problem called “uncontrolled narrow-angle glaucoma” • are allergic to solifenacin succinate or any of the ingredients in solifenacin succinate tablets. See the end of this leaflet for a complete list of ingredients. What should I tell my doctor before taking solifenacin succinate tablets? Before you take solifenacin succinate tablets, tell your doctor if you: • have any stomach or intestinal problems or problems with constipation • have trouble emptying your bladder or you have a weak urine stream • have an eye problem called “narrow-angle glaucoma” • have liver problems • have kidney problems • have a rare heart problem called “QT prolongation” • are pregnant or plan to become pregnant. It is not known if solifenacin succinate will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. • are breastfeeding or plan to breastfeed. It is not known if solifenacin succinate passes into your breast milk. You and your doctor should decide if you will take solifenacin succinate tablets or breastfeed. Tell your doctor about all the medicines you take , including prescription and nonprescription medicines, vitamins, and herbal supplements. Solifenacin succinate tablets may affect the way other medicines work, and other medicines may affect how solifenacin succinate tablets works. How should I take solifenacin succinate tablets? • Take solifenacin succinate tablets exactly as your doctor tells you to take it. • You should take 1 solifenacin succinate tablet 1 time a day. • You should take solifenacin succinate tablets with water and swallow the tablet whole. • You can take solifenacin succinate tablets with or without food. • If you miss a dose of solifenacin succinate tablets, begin taking solifenacin succinate tablets again the next day. Do not take 2 doses of solifenacin succinate the same day. • If you take too many solifenacin succinate tablets, call your doctor or go to the nearest hospital emergency room right away. What should I avoid while taking solifenacin succinate tablets? Solifenacin succinate tablets can cause blurred vision or drowsiness. Do not drive or operate heavy machinery until you know how solifenacin succinate tablets affect you. What are the possible side effects of solifenacin succinate tablets? Solifenacin succinate tablets may cause serious side effects including: • Serious allergic reaction. Stop taking solifenacin succinate tablets and get medical help right away if you have: o hives, skin rash or swelling o severe itching o swelling of your face, mouth or tongue o trouble breathing The most common side effects of solifenacin succinate tablets include: • dry mouth • constipation. Call your doctor if you get severe stomach area (abdominal) pain or become constipated for 3 or more days. • urinary tract infection • blurred vision Other side effects have been observed with anticholinergic drugs such as solifenacin succinate tablets and may include: • dry skin due to decreased sweating. Heat exhaustion or heat stroke can happen due to decreased sweating when solifenacin succinate tablets are used in hot environments. Symptoms may include: o decreased sweating o dizziness o tiredness o nausea o increase in body temperature Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of solifenacin succinate tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. How should I store solifenacin succinate tablets? • Store solifenacin succinate tablets at 59°F to 86°F (15°C to 30°C). Keep the bottle closed. • Safely throw away medicine that is out of date or no longer needed. Keep solifenacin succinate tablets and all medicines out of the reach of children. General information about the safe and effective use of solifenacin succinate tablets. Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use solifenacin succinate tablets for a condition for which it was not prescribed. Do not give solifenacin succinate tablets to other people, even if they have the same symptoms you have. It may harm them. This leaflet summarizes the most important information about solifenacin succinate tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about solifenacin succinate tablets that is written for health professionals. For more information, call Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115. What are the ingredients in solifenacin succinate tablets? Active ingredient : solifenacin succinate Inactive ingredients : corn starch, hypromellose, lactose monohydrate, magnesium stearate, talc, titanium dioxide and triacetin. The 5 mg tablets contain the colorants iron oxide yellow and FD&C yellow# 6. The 10 mg tablets contain the colorants iron oxide yellow and FD&C Red# 40 What is overactive bladder? Overactive bladder occurs when you cannot control your bladder contractions. When these muscle contractions happen too often or cannot be controlled you can get symptoms of overactive bladder, which are urinary frequency, urinary urgency, and urinary incontinence (leakage). Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: August 2025 glenmark-logo1"],"clinical_pharmacology_table":["
Table 2: QTc changes in msec (90% CI) from baseline at Tmax (relative to placebo)1
Drug/DoseFridericia method (using mean difference)
Solifenacin succinate 10 mg2 (-3,6)
Solifenacin succinate 30 mg8 (4,13)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. No adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at a dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (MRHD) of 10 mg/day. However, administration of doses 3.6 times and greater than the MRHD during organogenesis produced maternal toxicity in the pregnant mice and resulted in developmental toxicity and reduced fetal body weights in offspring [see Data] . In the U.S. general population, the estimated background risk of major birth defects or miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Oral administration of 14 C-solifenacin succinate to pregnant mice resulted in the recovery of radiolabel in the fetus indicating that solifenacin-related product can cross the placental barrier. In pregnant mice, administration of solifenacin succinate at a dose of 250 mg/kg/day (7.9 times the systemic exposure at the MRHD of 10 mg), resulted in an increased incidence of cleft palate and increased maternal lethality. Administration of solifenacin succinate to pregnant mice during organogenesis at greater than or equal to 3.6 times (100 mg/kg/day and greater) the systemic exposure at the MRHD, resulted in reduced fetal body weights and reduced maternal body weight gain. No embryo-fetal toxicity or teratogenicity was observed in fetuses from pregnant mice treated with solifenacin succinate at a dose of 30 mg/kg/day (1.2 times the systemic exposure at the MRHD). Administration of solifenacin succinate to pregnant rats and rabbits at a dose of 50 mg/kg/day (< 1 times and 1.8 times the systemic exposure at the MRHD, respectively), resulted in no findings of embryo-fetal toxicity. Oral pre- and post-natal administration of solifenacin succinate at 100 mg/kg/day (3.6 times the systemic exposure at the MRHD) during the period of organogenesis through weaning, resulted in reduced peripartum and postnatal survival, reduced body weight gain by the pups, and delayed physical development (eye opening and vaginal patency). An increase in the percentage of male offspring was also observed in litters from offspring (F2 generation) exposed to maternal doses of 250 mg/kg/day. There were no effects on natural delivery in mice treated with 1.2 times (30 mg/kg/day) the expected systemic exposure at the MRHD. 8.2 Lactation Risk Summary There is no information on the presence of solifenacin in human milk, the effects on the breastfed child, or the effects on milk production. Solifenacin is present in mouse milk [see Data] . When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for solifenacin succinate and any potential adverse effects on the breastfed child from solifenacin succinate or from the underlying maternal condition. Data Animal Data Oral administration of 14 C-solifenacin succinate to lactating mice resulted in the recovery of radioactivity in maternal milk. Lactating female mice orally administered solifenacin succinate at a maternally toxic dose of 100 mg/kg/day (3.6 times the systemic exposure at the MRHD) had increased postpartum pup mortality, pups with reduced body weights, or delays in the onset of reflex and physical development. Pups from lactating dams orally administered solifenacin succinate at a dose of 30 mg/kg/day (1.2 times the systemic exposure at the MRHD) had no discernible adverse findings. The concentrations of solifenacin in animal milk does not necessarily predict the concentration of drug in human milk. 8.4 Pediatric Use The safety and effectiveness of solifenacin succinate have not been established in pediatric patients. 8.5 Geriatric Use In placebo-controlled clinical studies, similar safety and effectiveness were observed between geriatric patients (623 patients ≥ 65 years and 189 patients ≥ 75 years) and younger adult patients (1188 patients < 65 years) treated with solifenacin succinate [ see Clinical Pharmacology ( 12.3 ) ]. 8.6 Renal Impairment Solifenacin plasma concentrations are greater in patients with severe renal impairment compared to subjects with normal renal function [ see Clinical Pharmacology ( 12.3 ) ]. Because increased solifenacin plasma concentrations increase the risk of antimuscarinic adverse reactions, the maximum recommended dose of solifenacin succinate in patients with severe renal impairment (CL cr < 30 mL/min/1.73 m 2 ) is 5 mg once daily [ see Dosage and Administration ( 2.2 ) ]. The recommended dose in patients with mild or moderate renal impairment is the same as in patients with normal renal function. 8.7 Hepatic Impairment Solifenacin plasma concentrations are greater in patients with moderate hepatic impairment compared to subjects with normal hepatic function [ see Clinical Pharmacology ( 12.3 ) ]. Because increased solifenacin plasma concentrations increase the risk of antimuscarinic adverse reactions, the maximum recommended dose of solifenacin succinate in patients with moderate hepatic impairment (Child-Pugh B) is 5 mg once daily [ see Dosage and Administration ( 2.3 ) ] and solifenacin succinate is not recommended for use in patients with severe hepatic impairment (Child-Pugh C). 8.8 Gender The pharmacokinetics of solifenacin is not significantly influenced by gender."],"package_label_principal_display_panel":["Package/Label Display Panel NDC 68462-386-30 Solifenacin Succinate Tablets, 5 mg 30 Tablets-Bottle label5mg30","Package/Label Display Panel NDC 68462-387-30 Solifenacin Succinate Tablets, 10 mg 30 Tablets-Bottle label10mg30"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No increase in tumors was found following the administration of solifenacin succinate to male and female mice for 104 weeks at doses up to 200 mg/kg/day (5 and 9 times, respectively, of the exposure at the maximum recommended human dose [MRHD] of 10 mg), and male and female rats for 104 weeks at doses up to 20 and 15 mg/kg/day, respectively (<1 times the exposure at the MRHD). Solifenacin succinate was not mutagenic in the in vitro Salmonella typhimurium or Escherichia coli microbial mutagenicity test or chromosomal aberration test in human peripheral blood lymphocytes with or without metabolic activation or in the in vivo micronucleus test in rats. Solifenacin succinate had no effect on reproductive function, fertility, or early embryonic development of the fetus in male and female mice treated with 250 mg/kg/day (13 times the exposure at the MRHD) of solifenacin succinate, and in male rats treated with 50 mg/kg/day (<1 times the exposure at the MRHD) and female rats treated with 100 mg/kg/day (1.7 times the exposure at the MRHD) of solifenacin succinate."]},"tags":[{"label":"Cholinergic Muscarinic Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M1","category":"target"},{"label":"CHRM1","category":"gene"},{"label":"CHRM5","category":"gene"},{"label":"CHRM3","category":"gene"},{"label":"G04BD08","category":"atc"},{"label":"Oral","category":"route"},{"label":"Suspension","category":"form"},{"label":"Tablet","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Bladder muscle dysfunction - overactive","category":"indication"},{"label":"Increased Urinary Frequency","category":"indication"},{"label":"Urge incontinence of urine","category":"indication"},{"label":"Urgent desire to urinate","category":"indication"},{"label":"Astellas","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Muscarinic Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Urological Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"3601 reports"},{"date":"","signal":"DRY MOUTH","source":"FDA FAERS","actionTaken":"1615 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"1614 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1275 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1236 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"1226 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1033 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"900 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"859 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"785 reports"}],"drugInteractions":[{"url":"/drug/atazanavir","drug":"atazanavir","action":"Monitor closely","effect":"May interact with Atazanavir, Solifenacin Succinate","source":"DrugCentral","drugSlug":"atazanavir"},{"url":"/drug/boceprevir","drug":"boceprevir","action":"Monitor closely","effect":"May interact with Boceprevir, Solifenacin Succinate","source":"DrugCentral","drugSlug":"boceprevir"},{"url":"/drug/clarithromycin","drug":"clarithromycin","action":"Monitor closely","effect":"May interact with Clarithromycin, Solifenacin Succinate","source":"DrugCentral","drugSlug":"clarithromycin"},{"url":"/drug/conivaptan","drug":"conivaptan","action":"Monitor closely","effect":"May interact with Conivaptan, Solifenacin Succinate","source":"DrugCentral","drugSlug":"conivaptan"},{"url":"/drug/indinavir","drug":"indinavir","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Solifenacin Succinate","source":"DrugCentral","drugSlug":"indinavir"},{"url":"/drug/itraconazole","drug":"itraconazole","action":"Monitor closely","effect":"May interact with Itraconazole, Solifenacin Succinate","source":"DrugCentral","drugSlug":"itraconazole"},{"url":"/drug/mibefradil","drug":"mibefradil","action":"Monitor closely","effect":"May interact with Mibefradil Dihydrochloride, Solifenacin Succinate","source":"DrugCentral","drugSlug":"mibefradil"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Monitor closely","effect":"May interact with Nefazodone, Solifenacin Succinate","source":"DrugCentral","drugSlug":"nefazodone"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Monitor closely","effect":"May interact with Nelfinavir Mesylate, Solifenacin Succinate","source":"DrugCentral","drugSlug":"nelfinavir"},{"url":"/drug/posaconazole","drug":"posaconazole","action":"Monitor closely","effect":"May interact with Posaconazole, Solifenacin Succinate","source":"DrugCentral","drugSlug":"posaconazole"},{"url":"/drug/ritonavir","drug":"ritonavir","action":"Monitor closely","effect":"May interact with Ritonavir, Solifenacin Succinate","source":"DrugCentral","drugSlug":"ritonavir"},{"url":"/drug/saquinavir","drug":"saquinavir","action":"Monitor closely","effect":"May interact with Saquinavir, Solifenacin Succinate","source":"DrugCentral","drugSlug":"saquinavir"},{"url":"/drug/telaprevir","drug":"telaprevir","action":"Monitor closely","effect":"May interact with Solifenacin Succinate, Telaprevir","source":"DrugCentral","drugSlug":"telaprevir"},{"url":"/drug/telithromycin","drug":"telithromycin","action":"Monitor closely","effect":"May interact with Solifenacin Succinate, Telithromycin","source":"DrugCentral","drugSlug":"telithromycin"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Monitor closely","effect":"May interact with Solifenacin Succinate, Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[{"effect":"Dry Mouth","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Constipation","drugRate":"13.4%","severity":"common","_validated":true},{"effect":"Urinary Tract Infection","drugRate":"4.8%","severity":"common","_validated":true},{"effect":"Blurred Vision","drugRate":"4.8%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"3.3%","severity":"mild","_validated":true},{"effect":"Dyspepsia","drugRate":"3.9%","severity":"mild","_validated":true},{"effect":"Abdominal Pain Upper","drugRate":"1.9%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"1.8%","severity":"mild","_validated":true},{"effect":"Urinary Retention","drugRate":"1.4%","severity":"mild","_validated":true},{"effect":"Edema Lower Limb","drugRate":"0.7%","severity":"mild","_validated":true},{"effect":"Fatigue","drugRate":"2.1%","severity":"mild","_validated":true},{"effect":"Influenza","drugRate":"2.2%","severity":"mild","_validated":true},{"effect":"Pharyngitis","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Vision Blurred","drugRate":"3.8%","severity":"mild","_validated":true},{"effect":"Dry Eyes","drugRate":"1.6%","severity":"mild","_validated":true},{"effect":"Cough","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Hypertension","drugRate":"0.5%","severity":"mild","_validated":true},{"effect":"Angioneurotic Edema","drugRate":"reported","severity":"unknown"},{"effect":"Severe Fecal Impaction","drugRate":"reported","severity":"unknown"},{"effect":"Colonic Obstruction","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal Obstruction","drugRate":"reported","severity":"unknown"},{"effect":"QT Prolongation","drugRate":"reported","severity":"unknown"},{"effect":"Torsade de Pointes","drugRate":"reported","severity":"unknown"},{"effect":"Atrial Fibrillation","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Palpitations","drugRate":"reported","severity":"unknown"},{"effect":"Liver Disorders","drugRate":"reported","severity":"unknown"},{"effect":"Renal Impairment","drugRate":"reported","severity":"unknown"},{"effect":"Glaucoma","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Angle-closure glaucoma","Bladder outflow obstruction","Congenital long QT syndrome","Disease of liver","Gastric retention","Gastrointestinal hypomotility","Gastrointestinal obstruction","Hepatic failure","Prolonged QT interval","Retention of urine","Torsades de pointes"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. No adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (MRHD) of 10 mg.","Geriatric use":"In placebo-controlled clinical studies, similar safety and effectiveness were observed between older (623 patients >=65 years and 189 patients >=75 years) and younger patients (1188 patients <65 years) treated with solifenacin succinate tablets. Multiple dose studies of solifenacin succinate tablets in elderly volunteers (65 to 80 years) showed that Cmax, AUC and t1/2 values were 20 to 25% higher as compared to the younger volunteers (18 to 55 years).","Paediatric use":"The safety and effectiveness of solifenacin succinate tablets in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Astellas Pharma","patents":[{"applNo":"N209529","source":"FDA Orange Book","status":"Active","expires":"May 18, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9918970","drugSubstance":false}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.2106/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$77","description":"SOLIFENACIN 10 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SOLIFENACIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:20:31.261168+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:20:31.260733+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:20:38.519507+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:20:29.882401+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:28.868558+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:28.868601+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:20:56.052436+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Muscarinic acetylcholine receptor M2 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:20:55.105836+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200803/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:20:54.844273+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA209239","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:28.868607+00:00"}},"allNames":"vesicare","offLabel":[],"synonyms":["YM-67905","YM-905","solifenacin","solifenacin succinate","vesicare"],"timeline":[{"date":"2004-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ASTELLAS to Astellas"},{"date":"2004-11-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Astellas)"},{"date":"2020-04-13","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 18 manufacturers approved"}],"aiSummary":"Vesicare (Solifenacin) is a small molecule cholinergic muscarinic antagonist developed by Astellas, targeting the muscarinic acetylcholine receptor M1. It is used to treat bladder muscle dysfunction, including overactive bladder, increased urinary frequency, urge incontinence of urine, and urgent desire to urinate. Vesicare was FDA approved in 2004 and is currently owned by Astellas. The drug has a half-life of 52 hours and 90% bioavailability. It is available as a generic medication with multiple manufacturers.","approvals":[{"date":"2004-11-19","orphan":false,"company":"ASTELLAS","regulator":"FDA"}],"brandName":"Vesicare","ecosystem":[{"indication":"Bladder muscle dysfunction - overactive","otherDrugs":[{"name":"butacaine","slug":"butacaine","company":""},{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"mirabegron","slug":"mirabegron","company":"Apgdi"}],"globalPrevalence":null},{"indication":"Increased Urinary Frequency","otherDrugs":[{"name":"butacaine","slug":"butacaine","company":""},{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"flavoxate","slug":"flavoxate","company":""}],"globalPrevalence":null},{"indication":"Urge incontinence of urine","otherDrugs":[{"name":"butacaine","slug":"butacaine","company":""},{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"oxybutynin","slug":"oxybutynin","company":""}],"globalPrevalence":null},{"indication":"Urgent desire to urinate","otherDrugs":[{"name":"butacaine","slug":"butacaine","company":""},{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"flavoxate","slug":"flavoxate","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M1","novelty":"Follow-on","targets":[{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"}],"moaClass":"Cholinergic Muscarinic Antagonists","modality":"Small Molecule","drugClass":"Cholinergic Muscarinic Antagonist","explanation":"Solifenacin is competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth.","oneSentence":"Vesicare works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle, reducing muscle contractions and urgency.","technicalDetail":"Vesicare selectively antagonizes the muscarinic acetylcholine receptor M1, which is responsible for the contraction of the detrusor muscle in the bladder. By blocking this receptor, Vesicare reduces the frequency and urgency of bladder contractions, providing relief from overactive bladder symptoms."},"commercial":{"launchDate":"2004","_launchSource":"DrugCentral (FDA 2004-11-19, ASTELLAS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2457","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SOLIFENACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SOLIFENACIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:41:43.934793","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:01.408246+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"flavoxate","drugSlug":"flavoxate","fdaApproval":"1970-01-15","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"oxybutynin","drugSlug":"oxybutynin","fdaApproval":"1975-07-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolterodine","drugSlug":"tolterodine","fdaApproval":"1998-03-25","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trospium","drugSlug":"trospium","fdaApproval":"2004-05-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"darifenacin","drugSlug":"darifenacin","fdaApproval":"2004-12-22","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fesoterodine","drugSlug":"fesoterodine","fdaApproval":"2008-10-31","patentExpiry":"Jun 7, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mirabegron","drugSlug":"mirabegron","fdaApproval":"2012-06-28","patentExpiry":"Sep 30, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"solifenacin","indications":{"approved":[{"name":"Bladder muscle dysfunction - overactive","source":"DrugCentral","snomedId":236633002,"regulator":"FDA"},{"name":"Increased Urinary Frequency","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Urge incontinence of urine","source":"DrugCentral","snomedId":87557004,"regulator":"FDA"},{"name":"Urgent desire to urinate","source":"DrugCentral","snomedId":75088002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Astellas","drugCategory":"mature","labelChanges":[],"relatedDrugs":[{"drugId":"flavoxate","brandName":"flavoxate","genericName":"flavoxate","approvalYear":"1970","relationship":"same-class"},{"drugId":"oxybutynin","brandName":"oxybutynin","genericName":"oxybutynin","approvalYear":"1975","relationship":"same-class"},{"drugId":"tolterodine","brandName":"tolterodine","genericName":"tolterodine","approvalYear":"1998","relationship":"same-class"},{"drugId":"trospium","brandName":"trospium","genericName":"trospium","approvalYear":"2004","relationship":"same-class"},{"drugId":"darifenacin","brandName":"darifenacin","genericName":"darifenacin","approvalYear":"2004","relationship":"same-class"},{"drugId":"fesoterodine","brandName":"fesoterodine","genericName":"fesoterodine","approvalYear":"2008","relationship":"same-class"},{"drugId":"mirabegron","brandName":"mirabegron","genericName":"mirabegron","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07473310","phase":"PHASE4","title":"Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-11-11","conditions":["Overactive Bladder (OAB)","Urge Incontinence"],"enrollment":70,"completionDate":"2027-12"},{"nctId":"NCT01530373","phase":"PHASE2","title":"Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2012-02","conditions":["Hot Flashes","Breast Cancer"],"enrollment":110,"completionDate":"2028-09"},{"nctId":"NCT07429734","phase":"PHASE3","title":"Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-02","conditions":["Overactive Bladder"],"enrollment":60,"completionDate":"2027-01"},{"nctId":"NCT07416968","phase":"PHASE4","title":"Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-09-01","conditions":["Overactive Bladder (OAB)","Overactive Bladder Syndrome"],"enrollment":480,"completionDate":"2026-12"},{"nctId":"NCT07305298","phase":"","title":"Mirabegron in Patients With Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"University of Naples","startDate":"2026-04-01","conditions":["Dry AMD","Overactive Bladder"],"enrollment":312,"completionDate":"2026-12-01"},{"nctId":"NCT07337252","phase":"","title":"Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-01","conditions":["Overactive Bladder"],"enrollment":61,"completionDate":"2024-08-31"},{"nctId":"NCT07312955","phase":"NA","title":"Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-05-15","conditions":["Overactive Bladder"],"enrollment":80,"completionDate":"2025-11-15"},{"nctId":"NCT06551246","phase":"PHASE3","title":"Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-06-27","conditions":["Urinary Incontinence in Children"],"enrollment":236,"completionDate":"2027-12-01"},{"nctId":"NCT06465576","phase":"PHASE4","title":"Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-05-27","conditions":["Urinary Incontinence in Children"],"enrollment":216,"completionDate":"2027-12-01"},{"nctId":"NCT06110975","phase":"NA","title":"Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anne Estrup Olesen","startDate":"2023-12-01","conditions":["Overactive Bladder","Deprescribing","PIMS"],"enrollment":72,"completionDate":"2026-12-01"},{"nctId":"NCT06489951","phase":"NA","title":"Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker","status":"COMPLETED","sponsor":"Xing Liu","startDate":"2024-12-28","conditions":["Overactive Bladder","Pediatric Disorder"],"enrollment":180,"completionDate":"2025-07-03"},{"nctId":"NCT07199894","phase":"PHASE3","title":"Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-12-01","conditions":["Nocturnal Enuresis in Children"],"enrollment":120,"completionDate":"2026-02-01"},{"nctId":"NCT06803030","phase":"PHASE3","title":"Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms","status":"RECRUITING","sponsor":"Bir Hospital","startDate":"2025-08-30","conditions":["Ureteral Stent-Related Symptom"],"enrollment":189,"completionDate":"2026-12-31"},{"nctId":"NCT07114640","phase":"PHASE3","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2025-08-07","conditions":["Urinary Bladder, Overactive"],"enrollment":220,"completionDate":"2028-12-31"},{"nctId":"NCT07114848","phase":"PHASE4","title":"Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ.","status":"COMPLETED","sponsor":"Liaquat National Hospital & Medical College","startDate":"2024-06-13","conditions":["Ureteral Stent-Related Symptom","Alpha Blocker","Anticholinergics","Ureter Calculi"],"enrollment":60,"completionDate":"2025-03-30"},{"nctId":"NCT07025642","phase":"NA","title":"Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes","status":"RECRUITING","sponsor":"Mackay Medical College","startDate":"2025-07-01","conditions":["Overactive Bladder (OAB)"],"enrollment":60,"completionDate":"2026-12-01"},{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":["Radiation Cystitis"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT05798403","phase":"NA","title":"Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder","status":"RECRUITING","sponsor":"Yin Ping","startDate":"2023-07-07","conditions":["Overactive Bladder"],"enrollment":204,"completionDate":"2025-12-31"},{"nctId":"NCT05968885","phase":"PHASE4","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2021-10-01","conditions":["Urinary Bladder, Overactive","Urodynamics","Effect of Drug"],"enrollment":300,"completionDate":"2026-12-31"},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":["Effect of Drug","Urinary Bladder, Overactive"],"enrollment":300,"completionDate":"2026-12-31"},{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":["Urinary Bladder, Overactive","Effect of Drug"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT06955533","phase":"NA","title":"Single Dose Versus Double Dose Tamsulosin 0.4 and Solifenacin 5 in Management of Stent Related Symptoms","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-04-01","conditions":["Stent Related Symptoms"],"enrollment":64,"completionDate":"2024-08-01"},{"nctId":"NCT06528613","phase":"","title":"Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.","status":"RECRUITING","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2024-10-23","conditions":["Benign Prostatic Hyperplasia"],"enrollment":450,"completionDate":"2025-09-30"},{"nctId":"NCT05067478","phase":"","title":"Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2021-10-28","conditions":["Overactive Bladder"],"enrollment":403,"completionDate":"2024-07-26"},{"nctId":"NCT01093534","phase":"PHASE4","title":"Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01-19","conditions":["Detrusor Overactivity","Overactive Bladder"],"enrollment":547,"completionDate":"2011-06-23"},{"nctId":"NCT01021332","phase":"PHASE3","title":"Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2010-04-26","conditions":["Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia"],"enrollment":1067,"completionDate":"2011-12-14"},{"nctId":"NCT01018511","phase":"PHASE3","title":"Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2010-01-11","conditions":["Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms"],"enrollment":1334,"completionDate":"2011-03-01"},{"nctId":"NCT01638000","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-06-12","conditions":["Urologic Diseases","Urinary Bladder, Overactive","Urinary Bladder Diseases"],"enrollment":1887,"completionDate":"2013-04-24"},{"nctId":"NCT01371994","phase":"PHASE4","title":"A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-08-02","conditions":["Urinary Incontinence"],"enrollment":640,"completionDate":"2013-10-21"},{"nctId":"NCT00629642","phase":"PHASE4","title":"Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-14","conditions":["Multiple Sclerosis","Neurogenic Bladder","Spinal Cord Diseases"],"enrollment":249,"completionDate":"2011-01-28"},{"nctId":"NCT01565694","phase":"PHASE3","title":"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-08-14","conditions":["Neurogenic Detrusor Overactivity"],"enrollment":76,"completionDate":"2016-04-28"},{"nctId":"NCT01655069","phase":"PHASE3","title":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-04","conditions":["Urinary Bladder, Overactive"],"enrollment":148,"completionDate":"2014-10-08"},{"nctId":"NCT01747577","phase":"PHASE4","title":"Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2012-12-04","conditions":["Overactive Bladder","Benign Prostate Hyperplasia","Transurethral Resection of Prostate","Photoselective Vaporization Prostatectomy"],"enrollment":68,"completionDate":"2013-10-24"},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":["Urologic Diseases","Urinary Bladder Diseases","Urological Manifestations","Signs and Symptoms","Urinary Bladder, Overactive"],"enrollment":1307,"completionDate":"2012-06-28"},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":["Urinary Bladder Diseases","Urinary Bladder Overactive","Urologic Diseases"],"enrollment":2174,"completionDate":"2014-11-25"},{"nctId":"NCT01565707","phase":"PHASE3","title":"A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-06-07","conditions":["Urinary Bladder, Overactive"],"enrollment":189,"completionDate":"2014-01-02"},{"nctId":"NCT02294396","phase":"PHASE4","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-28","conditions":["Overactive Bladder (OAB)"],"enrollment":649,"completionDate":"2016-09-07"},{"nctId":"NCT01981954","phase":"PHASE3","title":"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09-25","conditions":["Neurogenic Detrusor Overactivity","Pediatric"],"enrollment":23,"completionDate":"2015-12-18"},{"nctId":"NCT02045862","phase":"PHASE3","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-17","conditions":["Urinary Bladder Overactive","Overactive Bladder","Urgency Incontinence","Urinary Bladder Diseases\\Urologic Diseases"],"enrollment":1829,"completionDate":"2016-09-08"},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":["Urinary Bladder Overactive","Urinary Bladder Diseases\\Urologic Diseases","Overactive Bladder","Urgency Incontinence"],"enrollment":3527,"completionDate":"2015-10-22"},{"nctId":"NCT01539707","phase":"PHASE1","title":"Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-03-13","conditions":["Overactive Bladder","Neurogenic Detrusor Overactivity"],"enrollment":14,"completionDate":"2012-08-13"},{"nctId":"NCT01262391","phase":"PHASE1","title":"Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-20","conditions":["Urinary Bladder, Overactive"],"enrollment":42,"completionDate":"2011-08-14"},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":["Overactive Bladder (OAB)"],"enrollment":5589,"completionDate":"2019-09-13"},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":["Urinary Bladder Overactive","Overactive Bladder","Urinary Bladder Diseases","Urologic Diseases"],"enrollment":1524,"completionDate":"2017-08-04"},{"nctId":"NCT04819360","phase":"PHASE4","title":"Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis","status":"TERMINATED","sponsor":"Brigitte Schürch","startDate":"2021-06-01","conditions":["Urinary Bladder, Neurogenic","Multiple Sclerosis"],"enrollment":1,"completionDate":"2024-04-21"},{"nctId":"NCT03149809","phase":"PHASE3","title":"Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-03-01","conditions":["Overactive Bladder","Parkinson Disease"],"enrollment":77,"completionDate":"2023-09-08"},{"nctId":"NCT05282069","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2022-05-12","conditions":["Overactive Bladder"],"enrollment":607,"completionDate":"2024-05-29"},{"nctId":"NCT03106623","phase":"PHASE2","title":"Study of ONO-8577 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-04-07","conditions":["Overactive Bladder"],"enrollment":207,"completionDate":"2017-09-26"},{"nctId":"NCT06184334","phase":"NA","title":"Management of OAB in Female Patients .","status":"COMPLETED","sponsor":"Elsayed Abdelhalim Elsayed","startDate":"2022-09-14","conditions":["Overactive Bladder"],"enrollment":300,"completionDate":"2023-12-01"},{"nctId":"NCT05709990","phase":"NA","title":"Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children","status":"COMPLETED","sponsor":"Xing Liu","startDate":"2023-01-15","conditions":["Overactive Bladder"],"enrollment":303,"completionDate":"2023-06-15"},{"nctId":"NCT03817931","phase":"PHASE4","title":"Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2019-08-05","conditions":["Overactive Bladder","Dementia","Lower Urinary Tract Symptoms","Incontinence, Urge"],"enrollment":12,"completionDate":"2022-02-26"},{"nctId":"NCT06201013","phase":"NA","title":"Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children","status":"UNKNOWN","sponsor":"Xing Liu","startDate":"2023-09-03","conditions":["Urinary Bladder, Overactive","Overactive Bladder","Urinary Incontinence, Urge"],"enrollment":150,"completionDate":"2024-10-15"},{"nctId":"NCT04023253","phase":"PHASE3","title":"Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2019-08-01","conditions":["Overactive Bladder Syndrome"],"enrollment":120,"completionDate":"2024-12-31"},{"nctId":"NCT06024005","phase":"NA","title":"Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Ege University","startDate":"2023-04-18","conditions":["Overactive Bladder","Overactive Bladder Syndrome"],"enrollment":34,"completionDate":"2023-05-24"},{"nctId":"NCT05911594","phase":"NA","title":"IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-02-14","conditions":["BOTOX","Percutaneous Tibial Nerve Stimulation"],"enrollment":128,"completionDate":"2023-02-14"},{"nctId":"NCT04437108","phase":"NA","title":"Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2020-07-04","conditions":["Overactive Bladder","Urinary Incontinence, Urge","Urgency-frequency Syndrome","Post Prostatectomy"],"enrollment":132,"completionDate":"2022-07-21"},{"nctId":"NCT05040984","phase":"","title":"Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2021-04-30","conditions":["Overactive Bladder Syndrome"],"enrollment":500,"completionDate":"2024-12-31"},{"nctId":"NCT02540707","phase":"PHASE4","title":"Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-09-08","conditions":["Overactive Bladder Syndrome"],"enrollment":113,"completionDate":"2020-08-26"},{"nctId":"NCT05767632","phase":"PHASE1","title":"Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-05-30","conditions":["Healthy"],"enrollment":30,"completionDate":"2022-10-25"},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":["Urinary Incontinence","Urgency Urinary"],"enrollment":20,"completionDate":"2021-10-31"},{"nctId":"NCT05494567","phase":"PHASE4","title":"Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-11-08","conditions":["Benign Prostatic Hyperplasia","Overactive Bladder"],"enrollment":60,"completionDate":"2022-08"},{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":["Voiding Disorders"],"enrollment":100,"completionDate":"2023-10"},{"nctId":"NCT00852696","phase":"NA","title":"Over Active Bladder Patients Having Sling Surgery","status":"TERMINATED","sponsor":"Cleveland Clinic Florida","startDate":"2008-02","conditions":["Overactive Bladder"],"enrollment":1,"completionDate":"2010-02"},{"nctId":"NCT05391425","phase":"","title":"The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function","status":"UNKNOWN","sponsor":"Istanbul University","startDate":"2021-06-03","conditions":["Urge Incontinence","Urgency-frequency Syndrome"],"enrollment":150,"completionDate":"2024-06-03"},{"nctId":"NCT05240456","phase":"PHASE1,PHASE2","title":"Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-02","conditions":["Voiding Disorders","Overactive Bladder"],"enrollment":70,"completionDate":"2022-12"},{"nctId":"NCT03787654","phase":"NA","title":"Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-03-01","conditions":["Mixed Urinary Incontinence","Urgency-predominant Mixed Urinary Incontinence"],"enrollment":282,"completionDate":"2023-06-30"},{"nctId":"NCT04477265","phase":"NA","title":"Efficacy of Biofeedback PFMT and Medication in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2016-06-16","conditions":["Overactive Bladder"],"enrollment":140,"completionDate":"2021-12-24"},{"nctId":"NCT04325880","phase":"PHASE3","title":"Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-12-01","conditions":["Ureteral Stent","Stent Related Symptoms"],"enrollment":240,"completionDate":"2022-07-01"},{"nctId":"NCT01018264","phase":"PHASE4","title":"Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2010-01","conditions":["Overactive Bladder in Parkinson's Disease"],"enrollment":23,"completionDate":"2014-08"},{"nctId":"NCT04909255","phase":"PHASE4","title":"Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2021-03-23","conditions":["Sjogren's Syndrome","Overactive Bladder Syndrome"],"enrollment":50,"completionDate":"2022-08-15"},{"nctId":"NCT04693897","phase":"","title":"Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-01","conditions":["Overactive Bladder Syndrome","Detrusor Overactivity"],"enrollment":400,"completionDate":"2022-12-31"},{"nctId":"NCT03572231","phase":"","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-19","conditions":["Overactive Bladder (OAB)"],"enrollment":805,"completionDate":"2020-03-30"},{"nctId":"NCT03566134","phase":"PHASE2","title":"A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-07-10","conditions":["Overactive Bladder"],"enrollment":306,"completionDate":"2019-12-27"},{"nctId":"NCT01499069","phase":"NA","title":"Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-02","conditions":["Overactive Bladder"],"enrollment":191,"completionDate":"2016-02"},{"nctId":"NCT01559389","phase":"PHASE4","title":"Incontinence & Intimate Partners: Assessing the Contribution of Treatment","status":"COMPLETED","sponsor":"Loyola University","startDate":"2012-03-09","conditions":["Urge Urinary Incontinence"],"enrollment":138,"completionDate":"2017-06-29"},{"nctId":"NCT02972268","phase":"PHASE3","title":"Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-02-01","conditions":["Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia"],"enrollment":780,"completionDate":"2018-08-14"},{"nctId":"NCT04064619","phase":"NA","title":"Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2018-01-01","conditions":["Voiding Disorders"],"enrollment":60,"completionDate":"2019-08-02"},{"nctId":"NCT02047032","phase":"NA","title":"Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2014-04","conditions":["Urinary Incontinence"],"enrollment":500,"completionDate":"2016-10"},{"nctId":"NCT01767519","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-03-01","conditions":["Overactive Bladder","Urinary Incontinence"],"enrollment":356,"completionDate":"2015-03-18"},{"nctId":"NCT02549196","phase":"PHASE2","title":"A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type","status":"COMPLETED","sponsor":"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","startDate":"2015-10-07","conditions":["Dementia of Alzheimer's Type"],"enrollment":28,"completionDate":"2017-09-28"},{"nctId":"NCT03662893","phase":"NA","title":"Behavioural Therapy With Checklist for Overactive Bladder","status":"COMPLETED","sponsor":"Ankara Training and Research Hospital","startDate":"2015-01-01","conditions":["Overactive Bladder"],"enrollment":120,"completionDate":"2018-04-15"},{"nctId":"NCT03632772","phase":"PHASE2","title":"Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2018-08-01","conditions":["Overactive Bladder Syndrome"],"enrollment":130,"completionDate":"2019-07-31"},{"nctId":"NCT03468465","phase":"PHASE4","title":"Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome","status":"UNKNOWN","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2018-05-04","conditions":["Urinary Incontinence"],"enrollment":110,"completionDate":"2019-03"},{"nctId":"NCT03558919","phase":"PHASE4","title":"Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2017-01-01","conditions":["Overactive Bladder"],"enrollment":81,"completionDate":"2017-12-30"},{"nctId":"NCT01166438","phase":"PHASE3","title":"Anticholinergic vs. Botox Comparison Study","status":"COMPLETED","sponsor":"NICHD Pelvic Floor Disorders Network","startDate":"2010-03","conditions":["Urge Urinary Incontinence","Overactive Bladder"],"enrollment":249,"completionDate":"2012-05"},{"nctId":"NCT00821184","phase":"PHASE3","title":"Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2006-09","conditions":["Overactive Bladder"],"enrollment":12,"completionDate":"2008-09"},{"nctId":"NCT01457573","phase":"PHASE4","title":"Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Timothy Boone, MD, PhD","startDate":"2011-10","conditions":["Lower Urinary Tract Symptoms"],"enrollment":10,"completionDate":"2014-07"},{"nctId":"NCT01745094","phase":"PHASE4","title":"A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10-01","conditions":["Overactive Bladder"],"enrollment":223,"completionDate":"2013-07-23"},{"nctId":"NCT02805452","phase":"PHASE3","title":"Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer","status":"TERMINATED","sponsor":"Center Eugene Marquis","startDate":"2016-07","conditions":["Overactive Bladder"],"enrollment":4,"completionDate":"2017-07-15"},{"nctId":"NCT00547378","phase":"PHASE4","title":"InSite for Over Active Bladder","status":"COMPLETED","sponsor":"MedtronicNeuro","startDate":"2007-10","conditions":["Urinary Incontinence, Urgency-frequency","Overactive Bladder"],"enrollment":571,"completionDate":"2016-08"},{"nctId":"NCT02129816","phase":"PHASE2,PHASE3","title":"Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2014-05","conditions":["Overactive Bladder","Urge Urinary Incontinence"],"enrollment":9,"completionDate":"2017-07-09"},{"nctId":"NCT01470001","phase":"NA","title":"The Effect of Solifenacin on Post Void Dribbling in Women","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-11","conditions":["Post-micturition Incontinence","Incontinence"],"enrollment":118,"completionDate":"2015-09"},{"nctId":"NCT02860065","phase":"PHASE2","title":"CPC-201 Alzheimer's Disease Type Dementia: PET Study","status":"WITHDRAWN","sponsor":"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","startDate":"2016-09-30","conditions":["Alzheimer's Disease"],"enrollment":0,"completionDate":"2017-06-30"},{"nctId":"NCT00909428","phase":"PHASE4","title":"Validation of a Real-time Urodynamic Measure of Urinary Urgency","status":"COMPLETED","sponsor":"Loyola University","startDate":"2007-01","conditions":["Overactive Bladder Syndrome"],"enrollment":51,"completionDate":"2009-02"},{"nctId":"NCT03038321","phase":"PHASE4","title":"Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2017-02-01","conditions":["Non-Muscle-invasive Bladder Cancer (NMIBC)","Bacillus Calmette-Guerin (BCG) Cystitis","Intra-vesical Instillation"],"enrollment":150,"completionDate":"2019-12"},{"nctId":"NCT03059134","phase":"PHASE3","title":"Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2015-04-28","conditions":["Urinary Incontinence","Overactive Bladder Syndrome"],"enrollment":168,"completionDate":"2016-04-27"},{"nctId":"NCT01486706","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Gabapentin in Treating Overactive Bladder","status":"COMPLETED","sponsor":"Michael E. Chua","startDate":"2010-10","conditions":["Urinary Urgency","Urinary Frequency","Nocturia","Incontinence","Detrusor Uninhibited Activity","Quality of Life"],"enrollment":94,"completionDate":"2015-01"},{"nctId":"NCT00773552","phase":"PHASE4","title":"Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder","status":"WITHDRAWN","sponsor":"Stamford Hospital","startDate":"2008-11","conditions":["Urinary Urge","Urge Incontinence","Overactive Bladder"],"enrollment":0,"completionDate":"2009-04"},{"nctId":"NCT02940314","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-03","conditions":["Overactive Bladder"],"enrollment":36,"completionDate":"2016-05"},{"nctId":"NCT02087098","phase":"","title":"A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-06","conditions":["Urinary Bladder, Overactive"],"enrollment":2000,"completionDate":"2016-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Suspension, Tablet","formulations":[{"form":"SUSPENSION","route":"ORAL","productName":"VESIcareLS"},{"form":"TABLET","route":"ORAL","productName":"SOLIFENACINE SUCCINATE"},{"form":"TABLET","route":"ORAL","productName":"Solifenacin Succinate"},{"form":"TABLET, COATED","route":"ORAL","productName":"Solifenacin Succinate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"SOLIFENACIN SUCCINATE"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Solifenacin"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Solifenacin Succinate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Solifenacin succinate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"solifenacin succinate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"solifenacin succinate10 mg"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"solifenacin succinate5 mg"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"VESIcare"},{"form":"TABLET, FILM COATED, EXTENDED RELEASE","route":"ORAL","productName":"solifenacin succinate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000022393","MMSL":"19082","NDDF":"008712","UNII":"A8910SQJ1U","VUID":"4024390","CHEBI":"CHEBI:135530","VANDF":"4021510","INN_ID":"8155","RXNORM":"322167","UMLSCUI":"C1099677","chemblId":"CHEMBL1200803","ChEMBL_ID":"CHEMBL1734","KEGG_DRUG":"D01269","DRUGBANK_ID":"DB01591","PUBCHEM_CID":"154059","SNOMEDCT_US":"407030007","IUPHAR_LIGAND_ID":"7483","SECONDARY_CAS_RN":"242478-38-2","MESH_DESCRIPTOR_UI":"D000069464"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Astellas Pharma US, Inc.","brandName":"VESIcare","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2004-","companyName":"Astellas","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"52.0 hours","clearance":"2.1 mL/min/kg","bioavailability":"90%","fractionUnbound":"0.02%","volumeOfDistribution":"8.2 L/kg"},"publicationCount":939,"therapeuticAreas":["Urology"],"atcClassification":{"source":"DrugCentral","atcCode":"G04BD08","allCodes":["G04BD08","G04CA53"]},"biosimilarFilings":[],"originalDeveloper":"Astellas","recentPublications":[{"date":"2026 Mar 28","pmid":"41902910","title":"Efficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis.","journal":"Pediatric nephrology (Berlin, Germany)"},{"date":"2026 Mar 19","pmid":"41854167","title":"Is urinary myelin basic protein the key to understanding the role of vitamin D supplementation in paediatric overactive bladder-dry? Results from a three-stage clinical investigation.","journal":"BJU international"},{"date":"2026 Mar","pmid":"41852351","title":"Rational Design of a Carbonyl Reductase Yields a Robust Biocatalyst for Industrial Synthesis of (R)-3-Quinuclidinol.","journal":"Biotechnology journal"},{"date":"2026 Mar 17","pmid":"41841338","title":"Efficacy of Solifenacin Combined with Biofeedback in Children with Neurogenic Detrusor Overactivity Caused by Primary Tethered Cord Syndrome.","journal":"Journal of child neurology"},{"date":"2026 Mar 13","pmid":"41826414","title":"Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturers":26,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Ajanta Pharma Ltd","Alembic","Alkem Labs Ltd","Amneal Pharms Co","Annora Pharma","Aurobindo Pharma","Bostal","Breckenridge","Chartwell Rx","Cipla","Glenmark Speclt","Jubilant Generics","Lannett Co Inc","Macleods Pharms Ltd","Msn","Novitium Pharma","Qilu","Rising","Sciegen Pharms","Sunshine","Teva Pharms Usa","Torrent","Unichem","Watson Labs Inc","Zydus Pharms"],"status":"approved","companyName":"Astellas","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"2004","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-11-19T00:00:00.000Z","mah":"ASTELLAS","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-05-20T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA210224"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-05-20T00:00:00.000Z","mah":"BOSTAL","brand_name_local":null,"application_number":"ANDA210281"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-05-26T00:00:00.000Z","mah":"ASTELLAS","brand_name_local":null,"application_number":"NDA209529"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-11-24T00:00:00.000Z","mah":"GLENMARK SPECLT","brand_name_local":null,"application_number":"ANDA209239"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-12-03T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":null,"application_number":"ANDA211657"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:01.408246+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}